Akademik Veri Yönetim Sistemi
JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE, 2019 (ESCI)
Aim: The aim of the current study is the evaluation of valproic add and Vincristine combination on neuroblastoma cancer cells and to answer the question if valproic add (VPA) increase Vincristine (VCR) antitumor effect on the neuroblastoma cancer line or not. Material and Method: The neuroblastoma cell line was grown in culture medium. The different dose of VCR (0.5, 1 and 2 mu g), VPA (5mM), VCR (0.5, 1 and 2 mu g) + VPA (5 mM) was applied on neuroblastoma cancer cell lines for 24 hours. 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyttetrazolium Bromide (MTT) cell viability, Anexin-V-FITC apoptosis, Total Antioxidant Capacity (TAC) and Total Oxidant Status (TOS) tests were done 24 hours after drug administration. Results: As a result of the tests, 2 mu g VCR and VCR VPA (2 mu g + 5mM) reduced cell proliferation compared to the negative control group (P<0.05). Discussion: According to our result, valproic acid increased vincristine effect and reduced viability of cancer cells more effective than vincristine alone.